Skip to content

Serotonin: all studies

Page 347 of 400: studies 3,461 to 3,470 of 3,999, newest first. Back to the serotonin overview

Research

The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats.

Journal of Pharmacology and Experimental Therapeutics August 2011 Masakuni Horiguchi, M Huang, Herbert Y. Meltzer

The role of 5-hydroxytryptamine (serotonin) (5-HT)(7) receptor antagonism in the actions of atypical antipsychotic drugs (APDs), e.g., amisulpride, clozapine, and lurasidone, if any, is uncertain. We examined the ability of 5-HT(7) receptor antagonism alone and as a component of amisulpride and lurasidone to reverse deficits in rat novel object recognition (NOR) produced by subchronic treatment...

The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.

Neuroscience Letters July 15, 2011 Makiko Kasai, Katsutoshi Shioda, Koichi Nisijima et al.

The use of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") as a recreational drug has spread worldwide. Fatal hyperthermia is a likely side effect of using MDMA in combination with monoamine oxidase inhibitors. However, most antidepressants do not pose a high risk of developing hyperthermia when used in conjunction with MDMA. Mirtazapine is a novel antidepressant and a potent 5-HT(2A)...

Importance of inter-hemispheric prefrontal connection in the effects of non-competitive NMDA receptor antagonists

The International Journal of Neuropsychopharmacology July 7, 2011 Xavier López-Gil, Laura Jiménez-Sánchez, Tamara Romón et al. 35 citations

Previous studies have shown that systemic, but not unilateral intra-prefrontal cortex administration of non-competitive NMDA antagonists, increased prefrontal activity, the cortical efflux of serotonin, and induced stereotypies. In this work we used in-vivo microdialysis and immunohistochemistry to test the hypothesis as to whether MK-801 and ketamine need to act on both prefrontal cortices to...

Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation

Pharmaceuticals July 5, 2011 Elena Puerta, Norberto Aguirre 6 citations

The amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is widely abused as a recreational drug due to its unique psychological effects. Of interest, MDMA causes long-lasting deficits in neurochemical and histological markers of the serotonergic neurons in the brain of different animal species. Such deficits include the decline in the activity of tryptophan hydroxylase in...

Sleep apnea in young abstinent recreational MDMA (“ecstasy”) consumers

Neurology July 4, 2011 Una D. Mccann, Francis P. Sgambati, Alan R. Schwartz et al. 1 citation

Background: Methylenedioxymethamphetamine (MDMA, "ecstasy") is a popular recreational drug of abuse and a selective brain serotonin neurotoxin.Functional consequences of MDMA neurotoxicity have defied ready characterization.Obstructive sleep apnea (OSA) is a common form of sleep-disordered breathing in which brain serotonin dysfunction may play a role.The present study sought to determine...

Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.

Drug Metabolism and Disposition July 1, 2011 Hong-Wu Shen, Xi-Ling Jiang, Ai-Ming Yu 29 citations

5-Methoxy-N,N,-dimethyltryptamine (5-MeO-DMT), an abused serotonergic indolealkylamine drug, was placed into Schedule I controlled substance status in the United States as of January 19, 2011. In previous studies, we have shown the impact of monoamine oxidase A and cytochrome P450 2D6 enzymes on 5-MeO-DMT metabolism and pharmacokinetics. The aim of this study was to investigate 5-MeO-DMT...

DOI: 10.1124/dmd.111.039107 (opens in new tab) Full text (opens in new tab) 5-MEO-DMT Nonlinear pharmacokinetics Drug metabolism Animal research

NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses

Nature June 15, 2011 Anita E. Autry, M. Adachi, E. Nosyreva et al.

Clinical studies consistently demonstrate that a single sub-psychomimetic dose of ketamine, an ionotropic glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist, produces fast-acting antidepressant responses in patients suffering from major depressive disorder, although the underlying mechanism is unclear. Depressed patients report the alleviation of major depressive disorder symptoms...

Estudos de farmacocinética dos alcalóides da ayahuasca

June 8, 2011 Ana Paula Salum Pires

\n O uso de substâncias alucinógenas há muito tempo é alvo de discussões, em virtude do grande número de adeptos que possui e das conseqüências que pode acarretar ao indivíduo e ao complexo contexto social no qual ele se enquadra na sociedade. Dentro desse panorama vem se destacando à utilização de uma bebida denominada ayahuasca, preparada pela infusão de plantas nativas da região da Bacia...

Potential Long-term Effects of MDMA on the Basal Ganglia–Thalamocortical Circuit: A Proton MR Spectroscopy and Diffusion-Tensor Imaging Study

Radiology June 3, 2011 Hua-Shan Liu, Ming‐Chung Chou, Hsiao‐Wen Chung et al. 20 citations

PURPOSE: To investigate the effects of 3,4-methylenedioxymethamphetamine (MDMA, commonly known as "ecstasy") on the alterations of brain metabolites and anatomic tissue integrity related to the function of the basal ganglia-thalamocortical circuit by using proton magnetic resonance (MR) spectroscopy and diffusion-tensor MR imaging. MATERIALS AND METHODS: This study was approved by a local...

MDMA & Cannabis: A Mini-Review of Cognitive, Behavioral, and Neurobiological Effects of Co-Consumption

Current Drug Abuse Reviews June 1, 2011 Sybille Schulz 15 citations

Although the prevalence of co-use of cannabis and 3,4 methylenedioxymethamphetamine (MDMA) is very common among polydrug users in western societies, few studies have tested the consequences on behavior, cognition or neurobiology. This review examines 23 articles published between 2002 and 2010 with an explicit focus on the combination, or administration, of MDMA and cannabis or cannabinoid...